Today: 20 May 2026
More power cuts ahead: SaskPower reschedules Jan. 7 outages after weekend disruptions
6 January 2026
1 min read

More power cuts ahead: SaskPower reschedules Jan. 7 outages after weekend disruptions

Regina, Saskatchewan, Jan 6, 2026, 10:14 CST

  • SaskPower rescheduled intermittent, one-hour planned outages to Wednesday, Jan. 7, running 11 a.m. to 4 p.m.
  • Weekend outages in southwest Saskatchewan affected about 5,500 customers, the utility said.
  • SaskPower also carried out emergency pole repairs near Carmichael and Gull Lake, affecting customers west of Highway 37.

SaskPower has rescheduled a series of intermittent, one-hour planned outages to Wednesday in rural Saskatchewan, with customers north of D’Arcy to areas southwest of Stranraer expecting service interruptions between 11 a.m. and 4 p.m.

The change comes as the provincial utility works through the knock-on effects of weekend outages that affected about 5,500 customers in southwest Saskatchewan. SaskPower media relations consultant Scott McGregor said ice buildup on transmission lines in high winds triggered the disruptions.

SaskPower lists the Jan. 7 work as system maintenance. The outages are described as intermittent — meaning some customers may see power cut for about an hour at a time as crews move through the system.

The planned work follows an emergency shutdown on Sunday, when SaskPower said repairs to damaged power poles would require an outage from noon to 3 p.m. in a rural area southeast of Carmichael and south of Gull Lake, affecting customers west of Highway 37.

McGregor said crews restored most customers “within two or three hours.” Some were without power for “up to six or seven hours,” he said, as wind and ice slowed work in some locations.

SaskPower is Saskatchewan’s main supplier of electricity, serving more than half a million customers across a geographic area of about 652,000 square kilometres, according to the provincial government — a spread that can make storm-driven repairs logistically hard.

But the utility cautions that planned shutdowns can shift, and restoration timelines during unplanned outages can be affected by weather, location and safety constraints for crews working around live equipment.

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Tesla stock slides on Europe sales slump as BYD gains; traders eye Jan. 28 earnings
Previous Story

Tesla stock slides on Europe sales slump as BYD gains; traders eye Jan. 28 earnings

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure
Next Story

Fermi Inc (FRMI) stock jumps nearly 10% as class-action filing adds pressure

Go toTop